Pfizer Heritage in Biologics
Biosimilars provide the potential to offer a broader range of treatment options for patients, providers, and payers.

As potentially more affordable alternatives to originator biologics that have lost exclusivity, biosimilars may improve access and provide cost savings to healthcare systems.

Pfizer brings therapies to patients in over 175 markets in many therapeutic areas¹

Therapies include those that are:

- Small Molecules
  - Branded
  - Off-patent generic
- Biologics
  - Innovative
  - Biosimilar

Over 30 years of experience manufacturing biologics at the industry’s leading edge²

Nearly 10 years of experience outside the US manufacturing biosimilars³

Investing in biosimilars with a focus on inflammation and oncology⁴

---

Pfizer Has the Infrastructure and Experience to Support a Global Biosimilars Business That Leverages Pfizer’s Strong Capabilities and Footprint Across Our Value Chain

Pfizer Biosimilars Value Chain

Technical Development
Manufacturing and Global Supply
Clinical Development and Regulatory Affairs
Commercial Model and Global Presence

Pfizer’s Culture of Quality Forms the Foundation for Excellence in Manufacturing Biosimilars

- Rich history of innovation in manufacturing
- Quality-by-design principles for production
- Commitment to continuous improvement process
- Current Good Manufacturing Practice (CGMP) standards in quality control, supported by advanced technologies and scientific expertise
- State-of-the-art production, informed by proprietary design and execution

1. DOF Certification of Pfizer Biosimilar Claims 2016.
Pfizer’s Culture of Quality Helps Patients to Benefit From a Sustainable Supply of Quality Products

- Through consistent high standards for quality, compliance, and supply reliability, Pfizer’s global supply network provides
  - Fast, flexible solutions across the full manufacturing and supply chain spectrum
  - Delivery of quality medicines around the world

Pfizer Brings Innovation for Sustainable Healthcare

- Developing innovative treatments
- Developing biosimilars to innovative treatments for sustainable healthcare and potentially expanded access
Pfizer Biosimilars in Market

- Three marketed biosimilars outside the US\(^1\)
- Four mAbs in Phase 3\(^2\)
- Investing in biosimilars with a focus on inflammation and oncology\(^2\)

\(^1\) European Medicines Agency Website. European Public Assessment Reports for Retacrit, Nivestim, and Inflectra.
\(^2\) Pfizer Pipeline Update. February 2, 2016.
Key Points

- Biosimilars have the potential to offer a broader range of treatment options for patients, physicians, and payers.

- Leveraging Pfizer’s global presence and expertise in research and development, regulatory science, and commercialization will help deliver high-quality and effective biosimilars to patients with difficult-to-treat diseases.

- Pfizer Biosimilars will help continue Pfizer’s commitment to providing additional options in inflammation and oncology treatments that impact the lives of patients worldwide.
Thank You!